Pharmacotherapeutic options for overweight adolescents

Annals of Pharmacotherapy

Volumn 41, Issue 9, 2007, Pages 1445-1455

  Dunican, Kaelen C ^a,b   Desilets, Alicia R ^a   Montalbano, Julie K ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b Massachusetts College of Pharmacy and Health Sciences Worcester ^*  (United States)

Author keywords

Adolescents; Metformin; Obesity; Orlistat; Sibutramine

Indexed keywords

AMFEBUTAMONE; AMFEPRAMONE; ANOREXIGENIC AGENT; ANTICONVULSIVE AGENT; CALCIUM; CANNABINOID RECEPTOR ANTAGONIST; CHOLESTEROL; COPPER; EXENDIN 4; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAGNESIUM; METFORMIN; MULTIVITAMIN; NORADRENALIN; PHENTERMINE; PHOSPHORUS; PLACEBO; RIMONABANT; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; TRIACYLGLYCEROL; UNINDEXED DRUG; VITAMIN; ZINC; ZONISAMIDE;

ABDOMINAL DISCOMFORT; ADOLESCENT DISEASE; ANOREXIA; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DEFECATION; DEPRESSION; DIARRHEA; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; EMBASE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; MEDLINE; NAUSEA; OBESITY; PRIORITY JOURNAL; PULSE RATE; QT PROLONGATION; SIDE EFFECT; STEATORRHEA; SUICIDAL IDEATION; TACHYCARDIA; TREATMENT PLANNING; VITAMIN BLOOD LEVEL; WEIGHT REDUCTION; XEROSTOMIA;

ADOLESCENT; ANTI-OBESITY AGENTS; CLINICAL TRIALS; CYCLOBUTANES; HUMANS; HYPOGLYCEMIC AGENTS; LACTONES; METFORMIN; OBESITY; OVERWEIGHT;

EID: 34548165728     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K022     Document Type: Article

References (69)

1. Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA 2002;288:1728-32.
2. Ogden CL, Carroll MD, Flegal KM. Epidemiologic trends in overweight and obesity. Endocrinol Metab Clin North Am 2003;32:741-60, vii.
3. National Institutes of Health, National Heart, Lung and Blood Institute, North American Association for the Study of Obesity. The practical guide: identification, evaluation, and treatment of overweight and obesity in adults. NIH Publication 00-4084, October 2000 (online). www.nhlbi.nih.gov/guidelines/ obesity/prctgd_c.pdf (accessed 2007 Apr 28).
4. BMI-body mass index: about BMI for children and teens. CDC. www.cdc.gov/nccdphp/dnpa/bmi/childrens_BMI/about_childrens_BMI.htm (accessed 2007 Apr 28).
5. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006;295:1549-55. DOI 10.1001/jama.295.13.1549
6. Whitaker RC, Wright JA, Pepe MS, Seidel KD, Dietz WH. Predicting obesity in young adulthood from childhood and parental obesity. N Engl J Med 1997;337:869-73.
7. Goran MI, Ball GD, Cruz ML. Obesity and risk of type 2 diabetes and cardiovascular disease in children and adolescents. J Clin Endocrinol Metab 2003;88:1417-27.
8. The Surgeon General's call to action to prevent and decrease overweight and obesity. www.surgeongeneral.gov/topics/obesity/calltoaction/fact_adolescents firm (accessed 2007 Apr 28).
9. Freedman DS, Dietz WH, Srinivasan SR, Berenson GS. The relation of overweight to cardiovascular risk factors among children and adolescents: the Bogalusa Heart Study. Pediatrics 1999;103:1175-82.
10. Dietz WH. Health consequences of obesity in youth: childhood predictors of adult disease. Pediatrics 1998;101:518-25.
11. Must A, Strauss RS. Risks and consequences of childhood and adolescent obesity. Int J Obes Relat Metab Disord 1999;23(suppl 2):S2-11.
12. Weiss R, Dziura J, Burgert TS, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004;350:2362-74. DOI 10.1056/NEJMoa031049
13. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med 2003;157:821-37. DOI 10.1001/archpedi.157.8.821
14. Fowler-Brown A, Kahwati LC. Prevention and treatment of overweight in children and adolescents. Am Fam Physician 2004;69:2591-8.
15. Bays HE. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 2004;12:1197-211.
16. Yanovski JA. Intensive therapies for pediatric obesity. Pediatr Clin North Am 2001;48:1041-53.
17. Fontbonne A, Charles MA, Juhan-Vague I, et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO study group. Diabetes Care 1996;19:920-6.
18. Charles MA, Eschwege E, Grandmottet P, et al. Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial. Diabetes Metab Res Rev 2000;16:2-7. DOI 10.1002/(SICI) 1520-7560(200001/02)
19. Astrup A, Caterson I, Zelissen P, et al. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res 2004;12:1658-69.
20. Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M, OBES-002 Study Group. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord 2004;28:1399-410. DOI 10.1038/sj.ijo.0802783
21. Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PM. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 2002;10:633-41.
22. Gadde KM, Parker CB, Maner LG, et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res 2001;9:544-51.
23. Jain AK, Kaplan RA, Gadde KM, et al. Bupropion SR vs placebo for weight loss in obese patients with depressive symptoms. Obes Res 2002;10:1049-56.
24. Keating GM. Exenatide. Drugs 2005;65:1681-92.
25. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100.
26. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91.
27. Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003;289:1820-5.
28. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001;107:E55. http://pediatrics. aappublications.org/cgi/reprint/107/4/e55) (accessed 2007 Jan 3).
29. Kay JP, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 2001;50:1457-61. DOI 10.1053/meta.2001.28078
30. Srinivasan S, Ambler GR, Baur LA, et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab 2006;91:2074-80. DOI 10.1210/jc.2006-0241
31. Fu JF, Liang L, Zou CC, et al. Prevalence of the metabolic syndrome in Zhejiang Chinese obese children and adolescents and the effect of metformin combined with lifestyle intervention. Int J Obes 2007;31:15-22. DOI 10.1038/sj.ijo0803453
32. Aarsen FK, van den Akker EL, Drop SL, Catsman-Berrevoets CE. Effect of topiramate on cognition in obese children (letter). Neurology 2006;67:1307-8.
33. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S, RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-97. DOI 10.1016/S0140-6736(05)66374-X
34. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761-75. DOI 10.1001/jama.295.7.761
35. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 2003;27:1437-46. DOI 10.1038/sj.ijo.0802475
36. Product information. Meridia (sibutramine hydrochloride monohydrate) capsules. North Chicago, IL: Abbott Laboratory, August 2006.
37. Product information. Xenical (orlistat) capsules. Nutley, NJ: Roche Laboratories, January 2005.
38. Zhi J, Melia AT, Eggers H, Joly R, Patel IH. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol 1995;35:1103-8.
39. Zhi J, Mulligan TE, Hauptman JB. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients. J Clin Pharmacol 1999;39:41-6.
40. Halford JC. Pharmacotherapy for obesity. Appetite 2006;46:6-10. DOI 10.1016/j.appet.2005.07.010
41. Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European orlistat obesity study group. Obes Res 2000;8:49-61.
42. Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European multicentre orlistat study group. Lancet 1998;352:167-72.
43. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999;281:235-42.
44. Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 2000;24:306-13.
45. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000;9:160-7.
46. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61.
47. FDA CDER Division of Metabolic and Endocrine Drug Products (HFD-510). Clinical review for NDA 20-766/S018. www.fda.gov/cder/foi/esum/2003/20766se5- 018_Orlistat_BPCA_CLINICAL_ltr.pdf (accessed 2007 Jan 8).
48. FDA approves orlistat for over-the-counter use. www.fda.gov/bbs/topics/ NEWS/2007/NEW01557.html (accessed 2007 Apr 28).
49. McDuffie JR, Calis KA, Uwaifo GI, et al. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res 2002;10:642-50.
50. McDuffie JR, Calis KA, Uwaifo GI, et al. Efficacy of orlistat as an adjunct to behavioral treatment in overweight African American and Caucasian adolescents with obesity-related co-morbid conditions. J Pediatr Endocrinol Metab 2004;17:307-19.
51. Norgren S, Danielsson P, Jurold R, Lotbom M, Marcus C. Orlistat treatment in obese prepubertal children: a pilot study. Acta Paediatr 2003;92:666-70.
52. Ozkan B, Bereket A, Turan S, Keskin S. Addition of orlistat to conventional treatment in adolescents with severe obesity. Eur J Pediatr 2004;163:738-41.
53. Maahs D, de Sema DG, Kolotkin RL, et al. Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr Pract 2006;12:18-28.
54. Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005;293:2873-83. DOI 10.1001/jama.293.23.2873
55. Zhi J, Moore R, Kanitra L. The effect of short-term (21-day) orlistat treatment on the physiologic balance of six selected macrominerals and microminerals in obese adolescents. J Am Coll Nutr 2003;22:357-62.
56. McDuffie JR, Calis KA, Booth SL, Uwaifo GI, Yanovski JA. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy 2002;22:814-22.
57. Smith IG, Goulder MA, On behalf of the Members of the Sibutramine Clinical Study 1047 Team. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001;50:505-12.
58. Porter JA, Raebel MA, Conner DA, et al. The long-term outcomes of sibutramine effectiveness on weight (LOSE weight) study: evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization. Am J Manag Care 2004;10:369-76.
59. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005;353:2111-20. DOI 10.1056/NEJMoa050156
60. Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001;286:1331-9.
61. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM study group. Sibutramine trial of obesity reduction and maintenance. Lancet 2000;356:2119-25.
62. Berkowitz RI, Wadden TA, Tershakovec AM, Cronquist JL. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA 2003;289:1805-12. DOI 10.1001/jama.289.14.1805
63. Godoy-Matos A, Carraro L, Vieira A, et al. Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. J Clin Endocrinol Metab 2005;90:1460-5. DOI 10.1210/jc.2004-0263
64. Violante-Ortiz R, Del-Rio-Navarro BE, Lara-Esqueda A, et al. Use of sibutramine in obese Hispanic adolescents. Adv Ther 2005;22:642-9.
65. Berkowitz RI, Fujioka K, Daniels SR, et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Ann Intern Med 2006;145:81-90.
66. Garcia-Morales LM, Berber A, Macias-Lara CC, Lucio-Ortiz C, DelRio-Navarro BE, Dorantes-Alvarez LM. Use of sibutramine in obese Mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2006;28:770-82. DOI 10.1016/j.clinther.2006.05. 008
67. Reisler G, Tauber T, Afriat R, Bortnik O, Goldman M. Sibutramine as an adjuvant therapy in adolescents suffering from morbid obesity. Isr Med Assoc J 2006;8:30-2.
68. Beaston P. Clinical review for NDA 20-632.SE5-021. www.fda.gov/cder/foi/ esum/2005/020632s021_sibutramine_hydrochloride_clinical_BPCA.pdf (accessed 2007 Apr 28).
69. Barlow SE, Dietz WH. Obesity evaluation and treatment: expert committee recommendations. The Maternal and Child Health Bureau, Health Resources and Services Administration and the Department of Health and Human Services. Pediatrics 1998;102:E29. http://pediatrics.aappublications.org/cgi/reprint/102/ 3/e29 (accessed 2007 Apr 28).